Business
Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update
Not even the release of a positive announcement has been able to stop the Recce Pharmaceuticals Ltd (ASX: RCE) share price from dropping today.
In afternoon trade, the biotechnology company’s shares are down 2.5% to 94 cents.
What did Recce announce?
This afternoon Recce Pharmaceuticals announced that the European Patent Office has granted patents relating to Recce 327 (R327) and Recce 529 (R529).
R327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria. This includes their superbug forms.
Whereas R529 is a new synthetic polymer formulation with indication against viruses. Recce is currently undertaking initial studies of R529 to indicate any potential therapeutic effect…
-
Noosa News15 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn
-
General19 hours agoGerman palliative care doctor with alleged ‘lust for murder’ accused of killing 15 patients
-
Noosa News24 hours agoTributes flow for Geham wife and mother after husband charged with murder
-
Noosa News15 hours agoHow to find out your TikTok personality – and become a ‘citizen scientist’